Method Of Co-culturing Cells Patents (Class 435/373)
-
Patent number: 7816136Abstract: A method for growing stem cells comprising the steps of a providing stem cells with supporters said supporters being genetically modified in order to provide externally regulatable interactions between the supporters and the stem cells; supporters and stem cells are interchangeable upon genetic modification and interaction; applying an external signal for starting or stopping the interactions.Type: GrantFiled: December 6, 2006Date of Patent: October 19, 2010Inventor: Yu-hua Una Chen-Bettecken
-
Patent number: 7811821Abstract: This invention relates to the culture of dendritic cells from human embryonic stem (ES) cells. Human ES cells are first cultured into hematopoietic cells by co-culture with stromal cells. The cells now differentiated into the hematopoietic lineage are then cultured with GM-CSF to create a culture of myeloid precursor cells. Culture of the myeloid precursor cells with the cytokines GM-CSF and IL-4 causes functional dendritic cells to be generated. The dendritic cells have a unique phenotype, as indicated by their combination of cell surface markers.Type: GrantFiled: May 31, 2006Date of Patent: October 12, 2010Assignee: Wisconsin Alumni Research FoundationInventors: Igor I. Slukvin, James A. Thomson, Maksym A. Vodyanyk, Maryna E. Gumenyuk
-
Patent number: 7811782Abstract: Methods and devices for applying hemodynamic patterns to human/animal cells in culture are described. Hemodynamic flow patterns are measured directly from the human circulation and translated to a motor that controls the rotation of a cone. The cone is submerged in fluid (i.e., cell culture media) and brought into close proximity to the cells. Rotation of the cone creates time-varying shear stresses. This model closely mimics the physiological hemodynamic forces imparted on endothelial cells in vivo. A TRANSWELL coculture dish (i.e., a coculture dish comprising an artificial porous membrane) may be incorporated, permitting two, three, or more different cell types to be physically separated within the culture dish environment. In-flow and out-flow tubing may be used to supply media, drugs, etc. separately and independently to both the inner and outer chambers. The physical separation of the cell types permits each cell type to be separately isolated for analysis.Type: GrantFiled: January 10, 2008Date of Patent: October 12, 2010Assignee: Hemoshear, LLCInventors: Brett R. Blackman, Brian R. Wamhoff
-
Patent number: 7806937Abstract: The invention is directed to compositions and methods for reconstructing artificial female reproductive organs. The constructs and methods of the invention can be used for ameliorating congenital malformations and disorders of female reproductive tract using tissue engineered female reproductive organs, such as the uterus, vagina, cervix, and fallopian tubes. These tissue engineered female reproductive organs can be generated by perfusing cultured cell populations derived from cells of the female reproductive tissues, such as uterine, vaginal, cervical, fallopian tube epithelial cells as well as smooth muscle cells.Type: GrantFiled: November 15, 2002Date of Patent: October 5, 2010Assignee: Children's Medical Center CorporationInventors: Anthony Atala, James J. Yoo
-
Patent number: 7807389Abstract: Disclosed are compositions and methods related to joint inflammation diseases. Disclosed is the relationship between osteoclasts and inflammatory joint diseases and osteoclast precursor cells.Type: GrantFiled: March 12, 2004Date of Patent: October 5, 2010Assignee: University of RochesterInventors: Christopher T. Ritchlin, Sally A. Haas-Smith, Edward M. Schwarz
-
Publication number: 20100233130Abstract: A method of expanding/maintaining undifferentiated hematopoietic stem cells by obtaining unselected mononuclear cells; and seeding the mononuclear cells into a stationary phase plug-flow bioreactor in which a three dimensional mesenchymal/stromal cell culture has been pre-established, thereby expanding/maintaining undifferentiated hematopoietic stem cells.Type: ApplicationFiled: February 6, 2007Publication date: September 16, 2010Applicant: Pluristem Ltd.Inventor: Shai Meretzki
-
Patent number: 7795018Abstract: The present invention is to provide a multipotent cell wherein the sufficient amount necessary can be stably and conveniently supplied with a minimum invasion, that will not cause rejection at the time of cell transplantation, that has a potential to differentiate into various cells such as mesenchymal cells including bone, cartilage, skeletal muscle and fat, endothelial cells, myocardial cells, neurons, mesenchymal cells, myocardial cells, endothelial cells, neurons induced to differentiate from the multipotent cell, and a therapeutic agent/treating method comprising these as active ingredient. Peripheral blood mononuclear cells (PMBC) are cultured on fibronectin-coated plastic plates for 7 to 10 days. The generating cell population with a fibroblast-like morphology is derived from circulating CD14+ monocyte, with a unique phenotype of CD14+CD45+CD34+ type I collagen+.Type: GrantFiled: March 18, 2004Date of Patent: September 14, 2010Assignee: Keio UniversityInventors: Masataka Kuwana, Hiroaki Kodama
-
Patent number: 7795024Abstract: The present invention provides an apparatus and methods for expansion of hematopoietic stem cell numbers. The stem cells are cultured and differentiated cells and endogenous growth factors are removed (depleted), permitting long term culture and expansion of the stem cells. The hematopoietic stem cells are used in numerous therapeutic procedures.Type: GrantFiled: May 3, 2004Date of Patent: September 14, 2010Assignee: Insception Bioscience, Inc.Inventors: Gerard Madlambayan, Peter Zandstra
-
Patent number: 7790039Abstract: The present invention provides methods for enriching a heterogenous mixture of bone marrow or blood constituents for stem cells by removal of non-stem cell constituents comprising separation of the non-stem cell constituents using a tangential flow filtration device.Type: GrantFiled: November 18, 2004Date of Patent: September 7, 2010Assignee: Northwest Biotherapeutics, Inc.Inventors: Marnix L. Bosch, Patricia A. Lodge, Julie Anna McEarchern, Alton L. Boynton, Paul G. Hugenholtz
-
Patent number: 7785883Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system.Type: GrantFiled: March 15, 2006Date of Patent: August 31, 2010Assignee: Vax Design Corp.Inventors: William L. Warren, Robert Parkhill, Michael N. Nguyen, Guzman Sanchez-Schmitz, Heather Fahlenkamp, Russell Higbee, Donald Drake, III, Anatoly Kachurin, David Moe
-
Publication number: 20100215628Abstract: The invention provides a method for preparing cell populations with anti-tumor immune response activity, which includes co-culturing tumor and mononuclear cell in a three-dimensional cell culture device, separating and amplifying the cell populations with anti-tumor immune response activity from the cultures. The present invention, at the same time, discloses the cell populations with anti-tumor immune response activity obtained by the method and the kit comprising the cell populations.Type: ApplicationFiled: November 22, 2006Publication date: August 26, 2010Inventors: Hua Liu, Wei Yang
-
Patent number: 7781216Abstract: A purified preparation of primate embryonic stem cells is disclosed. This preparation is characterized by the following cell surface markers: SSEA-1 (?); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); and alkaline phosphatase (+). In a particularly advantageous embodiment, the cells of the preparation are human embryonic stem cells, have normal karyotypes, and continue to proliferate in an undifferentiated state after continuous culture for eleven months. The embryonic stem cell lines also retain the ability, throughout the culture, to form trophoblast and to differentiate into all tissues derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). A method for isolating a primate embryonic stem cell line is also disclosed.Type: GrantFiled: March 12, 2008Date of Patent: August 24, 2010Assignee: Wisconsin Alumni Research FoundationInventor: James A. Thomson
-
Patent number: 7776596Abstract: A tissue graft construct for use in repairing diseased or damaged tissues is provided. The tissue graft construct comprises a matrix composition selected from the group consisting of urinary bladder submucosa and stomach submucosa, and extracts and hydrolysates thereof, added endothelial cells, and at least one additional preselected, exogenous population of cells which enhance initiation of the formation vessel-like structures in the graft construct. The preselected population of cells can be a population of non-keratinized or keratinized epithelial cells or a population of mesodermally-derived cells selected from the group consisting of fibroblasts, smooth muscle cells, skeletal muscle cells, cardiac muscle cells, multi-potential progenitor cells, pericytes, osteogenic cells, and any other suitable cell type, preferably selected based on the tissue to be repaired. Methods for enhancing the vascularization in vivo of these tissue graft constructs and for preparing these graft constructs are also provided.Type: GrantFiled: May 2, 2003Date of Patent: August 17, 2010Assignee: Purdue Research FoundationInventor: Stephen F. Badylak
-
Patent number: 7771999Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the tissues of the immune system in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates and other materials in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system, coupled with disease models to provide a more complete representation of an immune response.Type: GrantFiled: March 12, 2008Date of Patent: August 10, 2010Assignee: VaxDesign Corp.Inventors: William L. Warren, Heather Fahlenkamp, Russell G. Higbee, Eric M. Mishkin, Guzman Sanchez-Schmitz, Michael D. Rivard, Santosh Pawar
-
Patent number: 7754482Abstract: The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.Type: GrantFiled: May 25, 2005Date of Patent: July 13, 2010Assignee: The Trustees of the University of PennsylvaniaInventors: James L. Riley, Carl H. June, Robert H. Vonderheide, Nicole Aqui, Megan M. Suhoski
-
Publication number: 20100167330Abstract: The development and function of living tissues depends largely on interactions between cells that can vary in both time and space; however, temporal control of cell-cell interaction is experimentally challenging. By employing a micromachined silicon substrate with moving parts, herein is disclosed the dynamic regulation of cell-cell interactions via direct manipulation of adherent cells with micron-scale precision. The inventive devices and methods allow mechanical control of both tissue composition and spatial organization. The inventive device and methods enable the investigation of dynamic cell-cell interaction in a multitude of applications, such as intercellular communication, spanning embryogenesis, homeostasis, and pathogenic processes.Type: ApplicationFiled: March 10, 2008Publication date: July 1, 2010Inventors: Sangeeta N. Bhatia, Elliot Hui
-
Publication number: 20100167398Abstract: Provided are a method of culturing pluripotent stem cells in the presence of a decidua-derived cell or an extracellular matrix derived from the cell, that enables safe and efficient maintenance culture and derivation of pluripotent stem cells; a culture agent for pluripotent stem cells, that comprises a decidua-derived cell or an extracellular matrix derived from the cell; and other means for developing or performing the method.Type: ApplicationFiled: December 23, 2009Publication date: July 1, 2010Applicant: RIKENInventors: Yoshiki SASAI, Tomoko NAGASE, Morio UENO, Yonehiro KANEMURA
-
Patent number: 7745140Abstract: Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.Type: GrantFiled: June 13, 2003Date of Patent: June 29, 2010Assignee: The Trustees of the University of PennsylvaniaInventors: Carl June, James Riley, Marcela Maus, Anna Thomas, Robert Vonderheide
-
Patent number: 7745120Abstract: The present invention provides a cell-culturing model and a method for screening compounds which can be applied in treating or preventing hepatic cirrhosis. The cell culturing model comprises a population of hepatocytes and hepatic stellate cells (HSCs) derived from co-culturing, and at least one population of the cells comprises a nucleotide sequence fragment of a reporter gene and a cell specific regulatory sequence. The cell-culturing model of the present invention can be applied in high throughput screening for effective compounds of medication, and also in understanding the functional mechanism of the effective compounds.Type: GrantFiled: December 12, 2005Date of Patent: June 29, 2010Assignee: Industrial Technology Research InstituteInventors: Wen-Tyng Li, Rung-Jiun Gau, Yu-Shih Weng, Cheng-Ta Hsieh, Pei-Shan Li
-
Patent number: 7741116Abstract: A device, and method of making the device, capable of therapeutic treatment and/or for in vitro testing of human skin. The device may be used on skin wounds for burned, injured, or diseased skin, and provides structures and functions as in normal uninjured skin, such as barrier function, which is a definitive property of normal skin. The device contains cultured dermal and epidermal cells on a biocompatible, biodegradable reticulated matrix. All or part of the cells may be autologous, from the recipient of the cultured skin device, which advantageously eliminates concerns of tissue compatibility. The cells may also be modified genetically to provide one or more factors to facilitate healing of the engrafted skin replacement, such as an angiogenic factor to stimulate growth of blood vessels.Type: GrantFiled: March 6, 2002Date of Patent: June 22, 2010Assignees: University of Cincinnati, Shriners Hospitals For ChildrensInventor: Steven T. Boyce
-
Patent number: 7736895Abstract: The invention provides methods for altering the expression profile of a cell to convert the cell from one cell type to a desired cell type. These reprogrammed cells may be used in a variety of medical applications for treating a mammal in need of a particular cell type.Type: GrantFiled: August 2, 2004Date of Patent: June 15, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Philippe Collas, James M. Robl
-
Patent number: 7736894Abstract: The present invention relates to a method for constructing human skin tissue, in which human skin tissue is reconstructed on a body surface of an immunodeficient non-human animal.Type: GrantFiled: May 18, 2004Date of Patent: June 15, 2010Assignee: Kao CorporationInventors: Akira Hachiya, Eiko Kaiho
-
Publication number: 20100143476Abstract: Cell based compositions and methods are provided for inducing the formation of vascular structures in a warm blooded vertebrate. In one embodiment the composition comprises purified endothelial progenitor cells and adipose stromal cells and the method of stimulating the formation of vascular structures comprises the steps of implanting the composition in a host organism.Type: ApplicationFiled: February 14, 2008Publication date: June 10, 2010Inventors: Keith L. March, Brian Johnstone, Dmity O. Traktuev
-
Patent number: 7732202Abstract: Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of O2 tension, including manipulation of Ca2+ under high O2 tension and contacting oocytes with serine threonine kinase inhibitors under low O2 tension, isolating inner cell masses (ICMs) from the activated oocytes, and culturing the cells of the isolated ICMs under high O2 tension. Moreover, methods are described for the production of stems cells from activated oocytes in the absence of non-human animal products, including the use of human feeder cells/products for culturing ICM/stem cells. Stem cells produced by the disclosed methods are also described.Type: GrantFiled: August 15, 2006Date of Patent: June 8, 2010Assignee: International Stem Cell CorporationInventors: Elena S. Revazova, Marina V. Pryzhkova, Leonid N. Kuzmichev, Jeffrey D. Janus
-
Publication number: 20100136685Abstract: The invention provides a method for transferring cells to carriers, including: (a) providing a hydrophobic cell culture container or a cell culture container coated with a hydrophobic material on a bottom thereof; (b) adding carriers which are more hydrophilic than the hydrophobic cell culture container or hydrophobic materials and a culture medium containing cells into the hydrophobic cell culture container or the cell culture container coated with the hydrophobic material on the bottom thereof; and (c) culturing the cells, wherein the cells attach to the carriers and grow.Type: ApplicationFiled: June 5, 2009Publication date: June 3, 2010Applicant: NATIONAL TAIWAN UNIVERSITYInventors: Chin-Hsiung Hsieh, Yi-You Huang
-
Publication number: 20100129906Abstract: A method for obtaining a stable xeno-free hBS cell line, xeno-free hBS cell lines obtained according to said method and use thereof.Type: ApplicationFiled: October 6, 2006Publication date: May 27, 2010Applicant: Cellartis ABInventors: Henrik Semb, Eva Karin Kilmare, Raimund Strehl, Catharina Ellerström, Katarina Frej, Karina Moya, Sven Johan Hyllner
-
Publication number: 20100129771Abstract: Disclosed is a method for producing a tooth, which comprises the steps of: positioning a first cell mass substantially comprising either one of amniotic mesenchymal cells or epithelial cells, and a second cell mass substantially comprising the other one in the inside of a support carrier while keeping them in close contact with each other without being mixed together; and culturing the first and second cell masses in the inside of the support carrier.Type: ApplicationFiled: February 28, 2008Publication date: May 27, 2010Applicants: ORGAN TECHNOLOGIES INC., THE KITASATO GAKUEN FOUNDATION, NIDEK CO., LTD.Inventors: Takashi Tsuji, Nobuo Sakuragawa
-
Patent number: 7709257Abstract: The present invention is directed to methods for constructing and using in vivo and in vitro models of aspects of human immunity and, in particular, construction of a human immune system model for the testing of, for example, vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals. The present invention comprises both in vivo and in vitro models of aspects of human immunity that are useful for assessing the interaction of substances with the immune system, and thus can be used to accelerate and improve the accuracy and predictability of, for example, vaccine, drug, biologic, immunotherapy, cosmetic and chemical development. The invention is also useful for the generation of human monoclonal and polyclonal antibodies.Type: GrantFiled: June 27, 2007Date of Patent: May 4, 2010Assignees: Vax Design Corp., Virginia Commonwealth UniversityInventors: John G. Tew, Mohey Eldin M. El Shikh, Inderpal Singh, Eric Mishkin, Donald Drake, III, Haifeng Song, William L Warren
-
Patent number: 7708977Abstract: A method for diagnosing decreased vascular function is disclosed. The method includes assaying the number of endothelial progenitor cells. A method for detecting increased cardiovascular risk is also disclosed, as is a method for diagnosing atherosclerosis. In one example, the methods include assaying the number of endothelial progenitor cells. A method for treating a subject with decreased vascular function is disclosed. The method includes administering a therapeutically effective amount of endothelial progenitor cells to the subject. In one embodiment, the subject has atherosclerosis.Type: GrantFiled: November 12, 2003Date of Patent: May 4, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Toren Finkel, Jonathan M. Hill, Arshed A. Quyyumi
-
Patent number: 7709256Abstract: The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising a three-dimensional matrix comprising lymphoid tissue, a three-dimensional matrix comprising epithelial and/or endothelial cells, and diseased cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals.Type: GrantFiled: June 15, 2006Date of Patent: May 4, 2010Assignee: Vaxdesign Corp.Inventors: William L. Warren, Russell Higbee, Eric Mishkin, Guzman Sanchez-Schmitz, Heather Fahlenkamp, Michael Rivard
-
Patent number: 7704745Abstract: An apparatus and methods for monitoring the status of a cell that consumes oxygen. In one embodiment of the present invention, the method includes the steps of confining the cell in a sensing volume, measuring dynamically intracellular or extracellular signaling of the cell, and determining the status of the cell from the measured intracellular or extracellular signaling of the cell.Type: GrantFiled: August 6, 2002Date of Patent: April 27, 2010Assignee: Vanderbilt UniversityInventors: Franz Baudenbacher, John P. Wikswo, R. Robert Balcarcel, David Cliffel, Sven Eklund, Jonathan Mark Gilligan, Owen McGuinness, Todd Monroe, Ales Prokop, Mark Andrew Stremler, Andreas Augustinus Werdich
-
Patent number: 7704495Abstract: This invention is intended to provide a method to quickly obtain a large amount of normal human chondrocytes or a mass thereof without fear of bacterial or viral infection. Namely, a method of producing human chondrocytes characterized by comprising co-culturing chondrocytes obtained from a cartilage having perichondrium, for example, auricular cartilage together with the perichondrium; and a method of producing human chondrocytes characterized by comprising monolayer or multilayer seeding the cultured cells once or more and culturing to give a chondrocyte mass.Type: GrantFiled: April 8, 2004Date of Patent: April 27, 2010Inventor: Hiroko Yanaga
-
Publication number: 20100099186Abstract: The present invention relates to methods and kits for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods, kits, and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.Type: ApplicationFiled: October 23, 2009Publication date: April 22, 2010Inventors: John M. Perry, Linheng Li, Justin C. Grindley
-
Patent number: 7695720Abstract: The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell inducibility, in which one, two, or several amino acids are substituted or added to the above-mentioned amino acid sequences, as well as pharmaceuticals for treating or preventing tumors, where the pharmaceuticals comprise these peptides. The peptides of this invention can be used as vaccines.Type: GrantFiled: January 16, 2009Date of Patent: April 13, 2010Assignee: Oncotherapy Science, Inc.Inventors: Hideaki Tahara, Satoshi Wada, Takuya Tsunoda
-
Patent number: 7695713Abstract: The present invention relates to improved autologous T cell vaccines and improved methods for their production. The invention is also directed to methods for treating autoimmune diseases such as multiple sclerosis or rheumatoid arthritis using autologous T cell vaccines. The invention is further directed to the diagnosis of T cell associated diseases.Type: GrantFiled: August 6, 2003Date of Patent: April 13, 2010Assignee: Baylor College of MedicineInventor: Jingwu Z. Zang
-
Patent number: 7691626Abstract: A self-contained cell culture apparatus and method of use in which a cell culture may be stored frozen for an extended period, then thawed, incubated and grown in a closed system without additional processing or added constituents. The apparatus and method readily lend themselves to automated handling and analysis by MEMS devices, and find particular application in micro gravity and/or high radiation environments. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope of the claims.Type: GrantFiled: November 22, 2004Date of Patent: April 6, 2010Assignee: The Regents of the University of CaliforniaInventors: Edward R. B. McCabe, Urvashi Bhardwaj, Zakir Rangwala, Yao Hua Zhang
-
Patent number: 7691369Abstract: Parenchymal cells are cultivated on cultivated endothelial cells or cultivated fibroblasts which have been separated by a surface of a specific hydrophilic polymer, and which have been patterned. A culture which contains thus formed patterned spheroids of cultivated parenchymal cells is thereby provided by this invention. This culture maintains a function which is specific to the parenchymal cells over a long period of time.Type: GrantFiled: September 8, 2008Date of Patent: April 6, 2010Assignee: Transparent Inc.Inventors: Kazunori Kataoka, Hidenori Otsuka, Teruo Okano, Yukio Nagasaki, Yasuhiro Horiike
-
Publication number: 20100075418Abstract: The present invention relates to a method for co-culture of stem cells using feeder cells, more particularly to a method for culturing stem cells by using a membrane having a number of pores to separate stem cells and feeder cells. In the present invention, the culture condition of stem cells optimized is provided, in which stem cells and feeder cells are cultivated independently in separate spaces while permeating essential substances selectively. The stem cells prepared in the present invention continue to remain indifferent and be supported by feeder cells until needing being sub-cultured. In addition, the stem cells even for therapeutic use can be obtained without any contaminant since not pretreated with a cytostatic agent such as mitomycin or irradiated. Therefore, the method for co-culturing stem cells by using a membrane of the present invention can be widely used for clinical applications.Type: ApplicationFiled: May 29, 2007Publication date: March 25, 2010Applicants: MODERN CELL & TISSUE TECHNOLOGIES, INC.Inventor: Hyun Sook Park
-
Patent number: 7682825Abstract: There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and/or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and/or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.Type: GrantFiled: February 6, 2003Date of Patent: March 23, 2010Assignee: Sanbio, Inc.Inventors: Mari Dezawa, Hajime Sawada, Hiroshi Kanno, Masahiko Takano
-
Patent number: 7678553Abstract: Strains of Lactobacillus which have been selected for their capability of reducing gastrointestinal inflammation, such as that due to Helicobacter pylori, and products derived from these strains, including agents for treatment or prophylaxis of inflammation associated with Helicobacter pylori for administration to humans and include conditioned media in which the selected strains have grown and protein-containing extracts of the conditioned media.Type: GrantFiled: December 3, 2008Date of Patent: March 16, 2010Assignee: Biogaia ABInventors: Eamonn Connolly, Bo Mollstam
-
Patent number: 7678573Abstract: A method of preparing a stromal cell conditioned medium useful in expanding undifferentiated hemopoietic stem cells to increase the number of the hemopoietic stem cells is provided. The method comprising: (a) establishing a stromal cell culture in a stationary phase plug-flow bioreactor under continuous flow on a substrate in the form of a sheet, the substrate including a non-woven fibrous matrix forming a physiologically acceptable three-dimensional network of fibers, thereby expanding undifferentiated hemopoietic stem cells; and (b) when a desired stromal cell density has been achieved, collecting medium from the stationary phase plug-flow bioreactor, thereby obtaining the stromal cell conditioned medium useful in expanding the undifferentiated hemopoietic stem cells.Type: GrantFiled: April 11, 2005Date of Patent: March 16, 2010Assignee: Pluristem Ltd.Inventors: Shoshana Merchav, Shai Meretski, Dov Zipori, Avinoam Kadouri
-
Publication number: 20100055076Abstract: A method for preparing dendritic cells which have an enhanced potential to suppress immune responses, method for suppressing immune response by comprising administering them, dendritic cells carrying a potential to suppress immune responses, and a pharmaceutical composition comprising the dendritic cells capable of inducing immunosuppressive responses. The present dendritic cells having an enhanced potential to suppress immune responses can be utilized for treating or preventing various diseases or disorders through the suppression of immune responses. In addition, the enhanced immunotolerance potential of the dendritic cells ensures the cells to be effectively used as an immunosuppressive agent.Type: ApplicationFiled: August 20, 2009Publication date: March 4, 2010Applicant: CREAGENE INC.Inventors: Dae Seog Lim, Ju Ah Jeong, Mi-Sun Kang, Hyun Soo Lee, Yong Soo Bae
-
Patent number: 7666673Abstract: The present invention provides a method of growing spermatogonial stem cells of mammals and the like in vitro, which is characterized in that glial cell-derived neurotrophic factor (GDNF) or an equivalent thereto, and leukemia inhibitory factor (LIF) are contained in a medium (culture broth) for culturing spermatogonial stem cells. According to the method of the present invention, spermatogonial stem cells can be grown in vitro to the extent that enables use thereof for developmental engineering.Type: GrantFiled: March 31, 2004Date of Patent: February 23, 2010Assignee: Kyoto UniversityInventors: Takashi Shinohara, Mito Shinohara
-
Publication number: 20100034793Abstract: The invention features a method for expanding and engrafting nucleated cells, e.g., progenitor cells, such as hematopoietic cells, obtained from cord blood by co-culturing the nucleated cells with adherent stroma cells, e.g., mesenchymal stem/progenitor cells, also obtained from cord blood.Type: ApplicationFiled: April 19, 2006Publication date: February 11, 2010Applicant: The John Hopkins UniversityInventors: Ian McNiece, Jin-Fu Wang
-
Publication number: 20100028308Abstract: The present invention relates to regulatory cells, which are capable of restoring, maintaining or improving the stable cartilage phenotype of expanded and passaged chondrocytes. These regulatory cells are also capable of directing precursor and stem cells into the chondrogenic lineage. An enriched population of regulatory cells can be obtained by harvesting the non-adherent cells in the culture medium of a monolayer culture of PO chondrocytes.Type: ApplicationFiled: March 20, 2007Publication date: February 4, 2010Applicant: Tigenix N.V.Inventors: Andreas Knipper, Paula Muir-McLeod
-
Publication number: 20100028997Abstract: The purpose is to proliferate a mesenchymal stem cell to a sufficient degree while reducing the amount of blood serum contained in a biological tissue progenitor cell to be grafted, and to efficiently differentiate the mesenchymal stem cell into the biological tissue progenitor cell. There is provided a method for culturing a mesenchymal stem cell, comprising: a first culture step of proliferating a mesenchymal stem cell in a medium containing blood serum; and a second culture step of differentiating the mesenchymal stem cell into a biological tissue progenitor cell in a medium containing blood serum at a lower concentration than that in the medium used in the first culture step.Type: ApplicationFiled: May 9, 2006Publication date: February 4, 2010Applicant: OLYMPUS CORPORATION,Inventor: Konghua Lin
-
Publication number: 20100021866Abstract: A first cell mass substantially containing only either one of mesenchymal cells or epithelial cells and a second cell mass substantially containing only the other one of the cells are positioned in contact with each other inside a support carrier which can maintain a condition of cell contact; and cultured to obtain a tooth having a specific cell placement. Preferably, after the culturing, the support carrier having both cell masses is cultured with kidney cells.Type: ApplicationFiled: May 30, 2006Publication date: January 28, 2010Applicant: TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATIONInventors: Takashi Tsuji, Kazuhisa Nakao
-
Patent number: 7651855Abstract: Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4+CD25+ suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use.Type: GrantFiled: April 19, 2004Date of Patent: January 26, 2010Assignee: The Trustees of the University of PennsylvaniaInventors: Bruce Blazar, Carl June, Wayne R. Godfrey, Richard G. Carroll, Bruce Levine, James L. Riley, Patricia Taylor
-
METHOD TO INDUCE AND EXPAND THERAPEUTIC ALLOANTIGEN-SPECIFIC HUMAN REGULATORY T CELLS IN LARGE-SCALE
Publication number: 20090324557Abstract: Methods for inducing, expanding, and/or generating alloantigen-specific regulatory T cells. Alloantigen-specific regulatory T cells can be induced, expanded, and/or generated from naive CD4+CD25?T cells by using CD40? activated B cells. The regulatory T cells can be human T cells. In one embodiment, the alloantigen-specific human regulatory T cells can be CD4hIghCD25+Foxp3+ regulatory T cells.Type: ApplicationFiled: April 30, 2009Publication date: December 31, 2009Inventors: Wenwei Tu, Yu-Lung Lau, David Bram Lewis -
Publication number: 20090317367Abstract: The present invention describes preadipocytes and methods of differentiating macrophages into preadipocytes by co-culturing adipocytes and resident adipose tissue macrophages. Also described are methods of increasing the proliferative rate of adipose adult stem/progenitor cells.Type: ApplicationFiled: February 21, 2008Publication date: December 24, 2009Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Gregorio Chazenbalk, Cristina Bertolotto, Ricardo Azziz, Charles F. Simmons, Jr., Saleh Heneidi